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Abstract 
Background: Erythema migrans (EM) is the most common manifestation of Lyme borreliosis. Here, we examined EM 
patients in Norwegian general practice to find the proportion exposed to tick‑transmitted microorganisms other than 
Borrelia, and the impact of co‑infection on the clinical manifestations and disease duration.
Methods: Skin biopsies from 139/188 EM patients were analyzed using PCR for Neoehrlichia mikurensis, Rickettsia 
spp., Anaplasma phagocytophilum and Babesia spp. Follow‑up sera from 135/188 patients were analyzed for spotted 
fever group (SFG) Rickettsia, A. phagocytophilum and Babesia microti antibodies, and tested with PCR if positive. Day 0 
sera from patients with fever (8/188) or EM duration of ≥ 21 days (69/188) were analyzed, using PCR, for A. phagocyt-
ophilum, Rickettsia spp., Babesia spp. and N. mikurensis. Day 14 sera were tested for TBEV IgG.
Results: We detected no microorganisms in the skin biopsies nor in the sera of patients with fever or prolonged EM 
duration. Serological signs of exposure against SFG Rickettsia and A. phagocytophilum were detected in 11/135 and 
8/135, respectively. Three patients exhibited both SFG Rickettsia and A. phagocytophilum antibodies, albeit negative 
PCR. No antibodies were detected against B. microti. 2/187 had TBEV antibodies without prior immunization. There 
was no significant increase in clinical symptoms or disease duration in patients with possible co‑infection.
Conclusions: Co‑infection with N. mikurensis, A. phagocytophilum, SFG Rickettsia, Babesia spp. and TBEV is uncom‑
mon in Norwegian EM patients. Despite detecting antibodies against SFG Rickettsia and A. phagocytophilum in some 
patients, no clinical implications could be demonstrated.
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Background
Lyme borreliosis (LB) is the most common tick-transmit-
ted infection in the Nordic countries and often presents 
clinically as a slowly expanding, erythematous skin lesion, 
known as erythema migrans (EM). It is caused by spiro-
chetes in the Borrelia burgdorferi sensu lato (Bbsl) group, 
which are carried and transmitted by Ixodes ricinus ticks, 
the medically most important tick species in northern 
Europe [1]. Apart from Bbsl, I. ricinus can harbor several 
other potentially pathogenic microorganisms, including 
species of spotted fever group (SFG) rickettsiae, Ana-
plasma phagocytophilum, Neoehrlichia mikurensis, Babe-
sia spp. and tick-borne encephalitis virus (TBEV) [2–7]. 
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Prior studies have demonstrated the concomitant pres-
ence of multiple microorganisms in questing ticks and 
transmission of more than one tick-borne microorganism 
has been reported in humans [8–11]. Despite this, little 
attention has been given to the incidence and clinical sig-
nificance of co-infection with multiple tick-transmitted 
agents in patients with EM. Furthermore, erythematous 
skin lesions, similar to those seen in EM, have been asso-
ciated with or attributed to N. mikurensis [12–15]. This 
relationship has, however, never been studied in a larger 
population sample and no causality has been established. 
Apart from N. mikurensis, skin manifestations can be 
observed in patients infected by other tick-borne micro-
organisms such as SFG rickettsiae and, less frequently, 
A. phagocytophilum [16–18]. As beta-lactam antibiot-
ics, the first-line treatment of patients with EM, are inef-
fective against most tick-borne microorganisms, it is 
important to determine to what extent EM skin lesions 
are co-infected with such microorganisms. Further, it is 
important to determine the clinical significance of such 
co-infection and the possibility of skin lesions, similar to 
EM, being caused by tick-transmitted microorganisms 
other than Bbsl.
In this study, we examined EM-patients from Nor-
way using molecular and serological methods to deter-
mine (1) the proportion exposed to tick-transmitted 
microorganisms other than Bbsl, and (2) the impact of 
co-infection on the clinical manifestations and disease 
duration of these patients.
Methods
Selection of study participants
The study was based on samples collected from 188 
patients clinically diagnosed with EM in Norwegian 
general practice during the years 2012–2013. The EM-
patients were originally enrolled in a clinical trial. Thus, 
the inclusion criteria and study patient characteristics are 
presented elsewhere [19]. A skin biopsy was taken from 
149/188 patients at the time of inclusion (day 0). DNA 
from Bbsl was detected in 104/149 (69.8%) skin biopsies 
using real-time PCR [19]. Serum samples from all 188 
patients were collected at day 0, day 14 and after 3 and 
12 months. Although samples were collected as part of a 
previous study, all analyses and results presented in this 
paper are new.
Molecular analyses
Real-time PCR for tick-borne microorganisms other 
than Bbsl was performed on 139 of the 149 skin biopsies 
already analyzed for Bbsl DNA (Fig. 1a) [19]. Ten of the 
149 biopsies contained an insufficient amount of material 
for further PCR analysis. Real-time PCR (conventional 
Fig. 1 a Flowchart describing molecular analyses of EM‑patients. b Flowchart describing serological analyses of EM‑patients. *Day 14 and 3‑month 
sera were additionally analyzed for TBEV (187/188) and Bbsl (175/188), respectively. †Patients with detectable IgG in the screening sample also had 
the remaining study samples tested for antibodies against the corresponding microorganisms
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PCR for Babesia spp.) was also performed on the inclu-
sion (day 0) serum samples of patients reporting fever 
during the initial 14  days (8/188) and patients with an 
EM duration of ≥ 21  days (69/188). This was done as 
fever is relatively uncommon in patients with EM but is 
often reported in infections caused by other tick-borne 
microorganisms. Two patients reported both fever and 
an EM duration ≥ 21 days.
Most of the molecular analyses were performed at 
Linköping University, Linköping, SE. A summary of the 
molecular methods is presented in Table 1a. Total nucleic 
acids were extracted from the patient specimens and 
turned into cDNA, as described elsewhere [20]. Differ-
ent real-time PCR assays were used to detect N. mikuren-
sis, Rickettsia spp., A. phagocytophilum and Babesia spp. 
Additional PCR analyses were performed on the inclu-
sion (day 0) samples of patients displaying a fourfold or 
higher rise in antibody titers against SFG Rickettsia spp., 
A. phagocytophilum or Babesia microti. The molecular 
analyses of sera for Babesia spp. was done using conven-
tional PCR at Statens Serum Institut, Copenhagen, DK, 
using the same primers and target gene as the real-time 
Babesia assay, as described elsewhere [21].
Real‑time PCR assays
Rickettsia spp.
Detection of Rickettsia spp. was done using a TaqMan 
real-time PCR assay, as previously described [22]. The 
primers CS-F and CS-R, and probe CS-P are designed 
to target the Rickettsia spp. citrate synthase gene (gltA) 
to amplify a 74-bp long amplicon (Table  1). As a posi-
tive control, a synthetic plasmid containing the target 
sequence of the TaqMan real-time PCR assay was used. 
The plasmid contained the target sequence, spanning the 
nucleotides 1102–1231 of the Rickettsia rickettsii gltA 
gene (GenBank: U59729), synthesized and cloned into 
pUC57 vector (GenScript). The assay has a limit of detec-
tion of 10 copies of the plasmid per reaction.
Anaplasma phagocytophilum
Detection of A. phagocytophilum was done using a 
TaqMan real-time PCR assay, as previously described 
Table 1 Overview of the reagents and assays used for the molecular (a) and serological (b) analyses
FAM 6-carboxy-fluorescine, BHQ Black Hole Quencher, MGB minor groove binder
a According to manufacturer’s instructions
b For Virion/Serion cut-offs are calculated for each batch according to manufacturer’s instructions
c For Euroimmun there is a fixed negative cut-off of < 120 VIEU/ml
(a)
Microorganism Primer/probe Nucleotide sequence (5′ → 3′) Target gene References
SFG Rickettsia spp. CS‑F TCG CAA ATG TTC ACG GTA CTTT gltA [22]
CS‑R TCG TGC ATT TCT TTC CAT TGTG 
CS‑P FAM‑TGC AAT AGC AAG AAC CGT AGG CTG 
GAT G‑BHQ1
A. phagocytophilum ApF TTT TGG GCG CTG AAT ACG AT gltA [6]
ApR TCT CGA GGG AAT GAT CTA ATA ACG T
ApM FAM‑TGC CTG AAC AAG TTATG‑BHQ1
N. mikurensis Forward CGG AAA TAA CAA AAG ATG GA groEL [12]
Reverse ACC TCC TCG ATT ACT TTA G
Probe 6FAM‑TTG GTG ATG GAA CTACA‑MGB
Babesia spp. BJ1 GTC TTG TAA TTG GAA TGA TGG 18S rRNA [24]
BN2 TAG TTT ATG GTT AGG ACT ACG 
(b)
Microorganism Method Manufacturer Antigen IgG cut‑off IgM cut‑off
SFG Rickettsia spp. Indirect IFA Focus Diagnostics Inactivated R. rickettsii 1:64 1:64
A. phagocytophilum Indirect IFA Focus Diagnostics Infected HL60 cells 1:64 1:20
Babesia microti Indirect IFA Focus Diagnostics Infected erythrocytes 1:64 –
Bbsl Indirect ELISA Enzygnost (Siemens) VlsE a –
TBEV Indirect ELISA 1. Virion/Serion
2. Euroimmun
1. Inactivated TBEV prepared 
from strain Moscow B‑4
2. Inactivated TBEV prepared 
from strain K23
1b.  2c –
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[6]. The primers ApF and ApR, and the probe ApM are 
designed to target the A. phagocytophilum citrate syn-
thase gene (gltA) to amplify a 64-bp long amplicon 
(Table 1). As a positive control, a synthetic plasmid con-
taining the target sequence of the TaqMan real-time 
PCR assay was used. The plasmid contained the target 
sequence, spanning the nucleotides 304–420 of the A. 
phagocytophilum gltA gene (GenBank: AF304137), syn-
thesized and cloned into pUC57 vector (GenScript, Pis-
cataway, NJ, USA). The assay has a limit of detection of 
30 copies of the plasmid per reaction.
Neoehrlichia mikurensis
Detection of N. mikurensis was done using a TaqMan 
real-time PCR assay, as previously described [12]. The 
primers and the probe are designed to target the N. miku-
rensis groEL gene to amplify a 169-bp long amplicon 
(Table  1). As a positive control, cDNA samples positive 
for N. mikurensis confirmed by sequencing in an earlier 
study [23] were used in each run.
Babesia spp.
Detection of Babesia spp. in the skin biopsies was done 
using a SYBR green real-time PCR assay, as previously 
described [24]. Primers BJ1 and BN2 are designed to 
target the Babesia 18S rRNA gene to amplify a 411–
452 bp long amplicon (Table 1). As a positive control, a 
synthetic plasmid containing the target sequence of the 
SYBR green real-time PCR assay was used. The plasmid 
contained the target sequence, spanning the nucleotides 
467–955 of the B. divergens 18S rRNA gene (GenBank: 
AJ439713), synthesized and cloned into pUC57 vector 
(GensSript). The assay has a limit of detection of 10 cop-
ies of the plasmid per reaction.
Serological analyses
Samples were analyzed using both indirect immuno-
fluorescence antibody (IFA) assays and ELISA assays as 
shown in Fig.  1b. A summary of the serological assays 
used is presented in Table  1b. All samples were exam-
ined using current serological “gold standards” with high 
reported sensitivities and specificities [25–27]. Of the 135 
patients who were serologically analyzed for other patho-
gens than Bbsl, 105 (78%) had their skin biopsies undergo 
molecular analysis using real-time PCR (Table 1a).
IFA
135 of the 188 patients had sufficient sera for further 
serological analyses using indirect IFA assays (Fig.  1b). 
Sufficient 3-month sera were available for 126 of these 
patients and were screened for the presence of IgG and 
IgM antibodies against SFG Rickettsia and A. phagocyt-
ophilum as well as IgG antibodies against B. microti. In 
patients missing 3-month sera, the day 14 sera (n = 8) 
and day 0 sera (n = 1) were screened instead (Fig. 1b).
The serological analyses for SFG Rickettsia, A. phago-
cytophilum and B. microti were done at SSI, Copenhagen 
DK, using commercially available IFA assays (Focus Diag-
nostics, Inc., Cypress, CA, USA). All samples were ana-
lyzed as part of the same experiment, exclusively for the 
present study. Samples were prepared according to the 
manufacturer’s instructions and all IFA samples under-
went two-fold dilutions until end-point fluorescence, as 
described in a previous study [28]. Samples were read in 
a dark room by two independent, experienced micros-
copists using a fluorescence microscope to establish the 
titer level. In cases of disagreement between the two 
microscopists, the sample was discarded and prepared 
again. Patients with detectable IgG antibodies in the 
screening sample had the remaining study samples fur-
ther tested for antibodies against the corresponding 
microorganisms. The time of inclusion was chosen as 
baseline and we interpreted a fourfold rise in IgG anti-
bodies at any of the follow-up visits (day 14, 3  months, 
12 months) as serological evidence of recent exposure for 
all IFA assays. Patients with only weak antibody reactivity 
as indicated by a rise in antibody level from < 1:64 to 1:64 
were excluded in the analyses. Further, a high IgG titer 
of ≥ 1:512 (clinical cut-off at SSI) or ≥ 1:128 (one titer 
above manufacturers recommendation) in at least one of 
the samples was considered evidence of prior exposure to 
SFG Rickettsia and A. phagocytophilum, respectively.
ELISA
Day 14 and 3-month sera were tested for IgG antibodies 
against TBEV (187/188) and Bbsl (175/188), respectively, 
using ELISA.
For TBEV, the analysis was done using a commercially 
available IgG ELISA assay (Virion/Serion, Würzburg, 
Germany) at the Norwegian Institute of Public Health 
(NIPH), Oslo NO. We chose to analyze the day 14 sam-
ples for TBEV as the time from tick bite or EM was, at 
this point, expected to be sufficient for any seroconver-
sion to have occurred. Equivocal results were retested 
using the same assay. Positive tests were reanalyzed with 
a different ELISA assay according to standard operating 
procedure (Euroimmun Anti-TBE Virus IgG, Lübeck, 
Germany).
The Bbsl analysis was performed at Sørlandet Hospital, 
Kristiansand NO, using a commercial ELISA kit (Enzyg-
nost Borrelia, Lyme link VlsE/IgG), as described else-
where [19]. At the time of inclusion, 50.0% of the patients 
(94/188) had detectable IgG antibodies against Bbsl [19] 
and to assess any further seroconversion, the 3-month 
sera were analyzed. For both Bbsl and TBEV, the IgG 
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cut-off levels were set in accordance with the manufac-
turers’ recommendations.
Clinical data
Data on concomitant symptoms was obtained through a 
patient diary kept for the first 14 days after inclusion [19]. 
The following 16 symptoms were inquired upon: tired-
ness, headache, arthralgia, neck stiffness, fever, palpita-
tions, myalgia, sore throat, tender skin, dizziness, nausea, 
chest pain, diarrhea, chills, hot flushes, and coughing. 
Further, clinical data on the size, duration, diagnostic 
accuracy and appearance of the EM lesions were col-
lected through clinical examination of the patients at 
days 0 and 14.
Statistical methods
For comparing proportions, we used a chi-squared test 
(Χ2) or a Fisher’s Exact Test when the expected number 
in one or more cells in the crosstabs was < 5. Means were 
compared with a t-test and for the continuous variables 
we used a Mann–Whitney U test. Missing data are con-
sidered to be randomly distributed. P-values ≤ 0.05 were 
considered statistically significant. Analyses were per-
formed using IBM SPSS Statistics for Windows (v. 25; 
IBM Corp., Armonk, NY, USA).
Results
Detection of microorganisms in biopsies and blood 
samples using molecular diagnostics
Neoehrlichia mikurensis, Rickettsia spp., A. phagocyt-
ophilum and Babesia spp. could not be detected in the 
skin biopsies (n = 139) using real-time PCR. Further, 
none of the above-mentioned microorganisms could 
be detected in the inclusion (day 0) serum samples of 
patients reporting fever (n = 8) or patients with an EM 
duration of ≥ 21 days (n = 69). For the latter, the amount 
of extractable samples was insufficient to perform analy-
ses in 15.4% (29/188) of the patients. Additional real-time 
PCR analysis on the inclusion (day 0) samples of patients 
displaying at least a fourfold rise in anti-Rickettsia IgG 
compared to baseline revealed no detectable Rickettsia 
DNA.
Serological analyses
An overview of the serological results is presented in 
Table  2. Four patients (cases 1–4; Table  2) displayed at 
least a fourfold rise in anti-Rickettsia IgG compared to 
baseline, one of whom displayed a concomitant rise in 
IgM antibodies (case 1; Table  2). 7/135 patients (5.2%) 
exhibited high anti-Rickettsia IgG titers of ≥ 1:512 in at 
least one of the samples (cases 5–11; Table 2).
For A. phagocytophilum, no patients displayed a four-
fold rise in IgG antibodies. However, 8/135 patients 
(5.9%) displayed increased levels of IgG at a titer 
of ≥ 1:128 in at least one of the samples (cases 12–16; 
Table  2). One of these patients had concomitant IgM 
antibodies against A. phagocytophilum (case 16; Table 2). 
Three patients exhibited antibody reactivity against both 
SFG Rickettsia and A. phagocytophilum (cases 1, 6 and 7; 
Table 2). No IgG antibodies could be detected against B. 
microti.
For TBEV, 9/187 patients (4.8%) displayed IgG anti-
bodies on the day 14 visit. Six of these patients reported 
prior immunization against TBEV and one had previ-
ously been immunized against Yellow Fever, suggesting 
cross-reactivity. The two remaining patients had no prior 
history of flavivirus immunization suggesting possible 
prior exposure to TBEV or some other flavivirus. Only 
one (case 15; Table 2) of the nine patients with detectable 
IgG against TBEV had serological evidence of exposure 
to other tick-borne pathogens. The IgG antibodies were 
in this case vaccine-induced.
Analysis of the 3-month sera showed that 50.3% 
(88/175) of patients had detectable Bbsl IgG. For the 16 
patients with serological evidence of co-infection, the 
proportion was 62.5% (10/16).
Clinical data
An overview of the clinical data for the patients display-
ing serological evidence of exposure to SFG Rickettsia 
and A. phagocytophilum is presented in Table 3. No sig-
nificant difference (p > 0.05) could be observed in the 
size, duration and appearance of the EM skin lesions 
or in the presence of concomitant symptoms between 
these patients and those without serological evidence of 
exposure to other tick-transmitted organisms than Bbsl. 
Among those with serological evidence of exposure to 
other tick-transmitted organisms than Bbsl, only one 
patient (case 14) reported fever. No fever or clinical signs 
of neuroinfection could be observed in the two patients 
displaying non-vaccine induced TBEV IgG during the 
study period.
Discussion
We found (1) no molecular evidence of other tick-borne 
microorganisms than Bbsl being present in the skin 
lesions of clinically diagnosed EM patients in Norwegian 
general practice and (2) a generally low proportion of 
these patients displaying serological evidence of exposure 
to the studied microorganisms. Of those displaying sero-
logical evidence of exposure, only four exhibited a signifi-
cant rise in IgG antibodies between the initial visit and 
follow-up, suggesting recent exposure.
These findings are in line with a previous Dutch study 
which examined 291 EM patients and detected DNA 
from other tick-borne microorganisms than Bbsl in the 
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EDTA-blood of only 8 (3%) using real-time PCR [13]. 
Given that PCR analysis of blood has been reported to 
have a lower sensitivity than serological analysis for sev-
eral tick-borne pathogens [25–27], it is possible that this 
was an underreporting of the true prevalence. A more 
recent study, combining serological and molecular meth-
ods of detection, also showed low rates of concomitant 
exposure to more than one tick-borne microorganism 
in EM patients diagnosed in the Nordic countries [11]. 
This latter study was, however, limited by a small study 
population, short follow-up and no examination of skin 
biopsies.
Strengths of our study include the use of both molecu-
lar and serological methods of detection, recruitment of 
Table 2 Overview of the EM patients displaying antibody reactivity against tick‑borne microorganisms other than Bbsl 
The titer values of the four patients displaying a fourfold rise in anti-Rickettsia IgG are printed in boldface
SFGR spotted fever group Rickettsia, Ap Anaplasma phagocytophilum
Case Sex Age Microorganism and 
antibody class
Serology 1 at day 
0 (baseline)
Serology 2 at 
day 14
Serology 3 after 
three months
Serology 4 after 
12 months
Bb. IgG 3 m
1 F 67 SFGR IgG  < 1:64 NA 1:128 1:128 POS
SFGR IgM  < 1:64  < 1:64 1:256
Ap IgG 1:64 NA 1:128 1:64
Ap IgM  < 1:20  < 1:20  < 1:20
2 M 27 SFGR IgG  < 1:64 1:128 – – –
SFGR IgM  < 1:64  < 1:64
3 M 85 SFGR IgG  < 1:64  < 1:64 1:128 1:128 POS
SFGR IgM  < 1:64  < 1:64  < 1:64  < 1:64
4 F 50 SFGR IgG  < 1:64  < 1:64 1:128  < 1:64 POS
SFGR IgM  < 1:64  < 1:64  < 1:64  < 1:64
5 M 65 SFGR IgG 1:1024 1:1024 1:256 1:512 POS
SFGR IgM  < 1:64  < 1:64  < 1:64  < 1:64
6 F 59 SFGR IgG 1:512 1:1024 1:512 1:1024 NEG
SFGR IgM  < 1:64  < 1:64  < 1:64  < 1:64
Ap IgG 1:128 1:128 1:128 1:64
Ap IgM  < 1:20  < 1:20  < 1:20  < 1:20
7 F 49 SFGR IgG 1:512 1:512 1:512 1:1024 NEG
SFGR IgM  < 1:64  < 1:64  < 1:64  < 1:64
Ap IgG 1:128 1:128 1:128 1:128
Ap IgM  < 1:20  < 1:20  < 1:20  < 1:20
8 M 24 SFGR IgG 1:2048 1:2048 ‑ ‑ ‑
SFGR IgM  < 1:64  < 1:64
9 M 76 SFGR IgG 1:512 1:512 1:256 1:256 POS
SFGR IgM  < 1:64  < 1:64  < 1:64  < 1:64
10 F 51 SFGR IgG 1:4096 1:4096 1:4096 1:4096 POS
SFGR IgM  < 1:64  < 1:64  < 1:64  < 1:64
11 M 49 SFGR IgG 1:512 1:512 1:256 1:512 NEG
SFGR IgM  < 1:64  < 1:64  < 1:64  < 1:64
12 F 76 Ap IgG 1:64 1:64 1:128 1:64 POS
Ap IgM  < 1:20  < 1:20  < 1:20  < 1:20
13 F 60 Ap IgG 1:128 1:128 1:64 1:64 POS
Ap IgM  < 1:20  < 1:20  < 1:20  < 1:20
14 F 59 Ap IgG 1:64 1:128 1:128 1:128 POS
Ap IgM  < 1:20  < 1:20  < 1:20  < 1:20
15 M 55 Ap IgG 1:64 1:64 1:64 1:128 NEG
Ap IgM  < 1:20  < 1:20  < 1:20  < 1:20
16 M 50 Ap IgG 1:128 1:128 1:64 1:128 POS
Ap IgM 1:40 1:40  < 1:20 20
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patients with a clinical diagnosis of EM in a general prac-
tice setting, a large proportion of PCR-verified EM skin 
lesions ascertaining a previous tick-bite and the use of 
both serum samples and skin biopsies for the analyses. 
Of the 105 patients who were analyzed with both PCR 
and serology, 70 (67%) had detectable Bbsl DNA in their 
skin biopsies [19], thus confirming a diagnosis of EM. 
14 of the 16 patients with serological evidence of other 
tick-borne infections had their skin biopsies analyzed for 
Bbsl in the original trial [19], with detectable Bbsl DNA 
being found in 12 (86%) of these biopsies, again con-
firming a high percentage of true EM lesions among the 
studied patients. The use of R. ricketsii as antigen could 
have reduced the sensitivity of our serological assay for 
other species of SFG Rickettsia. However, considering 
the general homology among species of SFG Rickettsia, 
we expect it to be capable of detecting other species of 
SFG Rickettsia as well, as has been suggested in a previ-
ous study [29]. Further, no serological assay for the detec-
tion of N. mikurensis was available at the time of this 
study. However, antibodies against A. phagocytophilum 
have been shown to cross-react with N. mikurensis [30] 
and the detected antibodies against A. phagocytophilum 
could thus represent exposure to N. mikurensis. Moreo-
ver, serum samples, and not whole blood, were used for 
parts of the PCR analyses which could have reduced the 
clinical sensitivity for some tick-transmitted microorgan-
isms such as the intraerythrocytic Babesia spp. Addi-
tional TBE testing in samples collected at three months 
might have revealed some additional seroconversions in 
patients with a longer than average incubation period 
or delayed humoral immune response. However, as the 
study was based on samples collected through a previous 
study [19], we used the patient material that was available 
to our disposal.
This study indicates that co-infections are rare in Nor-
wegian patients with EM. Antibodies against SFG Rick-
ettsia and A. phagocytophilum were detected in some of 
these patients. However, no significant difference in clini-
cal symptoms, appearance, or duration of EM skin lesions 
in patients with or without antibodies against SFG Rick-
ettsia and A. phagocytophilum, was detected. However, as 
only four of the patients displayed a fourfold rise in titer, 
it is impossible to tell if most of the detected antibodies 
Table 3 Clinical appearance of EM patients with or without exposition to other tick‑borne agents
IQR  interquartile range, SD  standard deviation
a Diagnostic accuracy scored by including GP, “not sure”, “sure” or “very sure”
b Number of the 16 symptoms registered: Tiredness, headache, arthralgia, neck stiffness, fever, palpitations, myalgia, sore throat, tender skin, dizziness, nausea, chest 
pain, diarrhea, chills, hot flushes, coughing
c Colour of the EM at the day of inclusion, grade 1–5 (light red—dark red).
d A = phenoxymethylpenicillin, B = Amoxicillin. C = Doxycycline. Treatments were randomized in the trial [19].
e X2-test
f t-test
g Mann–Whitney U test
h Fisher’s Exact Test
EM with possible co‑infection 
(n = 16)
EM without co‑infection (n = 119) p‑value
Statistics n Statistics N
Female, n (%) 8 (50%) 16 73 (61%) 118 0.36e
Age, mean (SD) 53.6 (20.7) 16 54.7 (15.3) 119 0.79f
Days from tick‑bite to EM, median (IQR) 21 (8–25) 11 11 (5–21) 74 0.21g
Days from EM to treatment, median (IQR) 5 (2–20) 15 7 (2–16) 103 0.87g
Diagnostic accuracy “very sure”a, n (%) 12 (75%) 16 81 (68%) 119 0.78h
EM duration, median (IQR) 14 (8–28) 16 14 (9–21) 119 0.66g
Concomitant  symptomsb, median (IQR) 2 (0–3) 16 1 (0–2) 119 0.50g
Fever, n (%) 1 (6.3%) 16 4 (3.4%) 117 0.48h
EM  colorc, mean (SD) 3.6 (0.89) 16 3.27 (0.89) 119 0.13f
EM diameter (cm), median (IQR) 10 (6–11) 16 10 (7–14) 116 0.69g
EM appearance “Bulls eye”, n (%) 11 (69%) 16 59 (50%) 117 0.16e
Bbsl biopsy pos., n (%) 12 (86%) 14 58 (66%) 88 0.22h
Antibiotic  treatmentd, n (%) A: 2 (13%)
B: 5 (31%)
C: 9 (56%)
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reflect recent exposure or prior infection unrelated to the 
current symptoms. A median duration of 21 days elapsed 
from the time of the tick-bite until the EM was noticed 
(Table  3) and it is likely that seroconversion occurred 
during this time frame for some of the patients. As infec-
tions with N. mikurensis have primarily been reported in 
chronically ill immunosuppressed patients [31–33], it is 
also important to emphasize that the participants of our 
study reported baseline general health at a comparable 
level to the background population and that active treat-
ment with immunosuppressants was an exclusion criteria 
for the original trial [19].
EM is a clinical diagnosis and in the Nordic countries 
the recommended treatment for EM without fever or 
other signs of disseminated disease is phenoxymethyl-
penicillin [34, 35]. Our study does not support a change 
in practice regarding this first-line treatment. Of note, 
44% of the participants displaying serological evidence 
of exposure to Rickettsia or Anaplasma received treat-
ment with phenoxymethylpenicillin or amoxicillin 
(Table 3), antibiotics with no effect on obligate intracel-
lular organisms.
Conclusions
Our study indicates that co-infections with N. mikuren-
sis, A. phagocytophilum, SFG Rickettsia, Babesia spp. and 
TBEV are uncommon in Norwegian patients with EM. 
Despite detecting antibodies against SFG Rickettsia and 
A. phagocytophilum in some of these patients, no clinical 
implications could be demonstrated, and the clinical sig-
nificance of these findings remains unknown.
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